Treatment with topical tazarotene results in partial or complete regression of most neoplasms in patients with basal cell cancer (BCC)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1455, 2004-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacokinetics and Drug Metabolism of Tazarotene: A Novel Topical Treatment for Acne and Psoriasis

By Tang-Liu D.-S.   Matsumoto R.M.   Usansky J.I.  

Clinical Pharmacokinetics, Vol. 37, Iss. 4, 1999-10 ,pp. : 273-287

Adis International

Access to resources Recommend Favorite

Diagnosis and Treatment of Patients with Testicular Germ Cell Cancer

By Hartmann J.T.   Kanz L.   Bokemeyer C.  

Drugs, Vol. 58, Iss. 2, 1999-08 ,pp. : 257-281

Adis International

Access to resources Recommend Favorite

Treatment options for basal cell carcinoma

By  

Inpharma, Vol. 1, Iss. 1408, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Dismal outcome of t‐cell lymphoma patients failing first‐line treatment: results of a population‐based study from the Modena Cancer Registry

By  

Hematological Oncology (Electronic), Vol. 33, Iss. 3, 2015-09 ,pp. : 147-151

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dismal outcome of t‐cell lymphoma patients failing first‐line treatment: results of a population‐based study from the Modena Cancer Registry

By  

Hematological Oncology (Electronic), Vol. 278-0232, Iss. 3, 2015-09 ,pp. : 147-151

John Wiley & Sons Inc

Access to resources Recommend Favorite